- Home
- Media Center
- Press releases
- Innovative Medicine
Innovative Medicine
Janssen Announces Expanded Collaboration with International Partnership for Microbicides for Development and Commercialization of Dapivirine for Prevention of Sexual Transmission of HIV
Latest innovative collaboration from the Janssen Global Public Health group and significant contribution to Johnson & Johnson’s wider efforts to improve public health worldwide
Study Found INVEGA® SUSTENNA® (paliperidone palmitate) Once-Monthly Long-Acting Therapy Delayed Time to and Reduced Risk of Relapse in Individuals with Schizoaffective Disorder as Monotherapy and Adjunctive Therapy
Demonstrated significant efficacy in manic and depressive mood symptoms and psychosis, and improved patient functioning
Landmark Study Shows Once-Monthly Long-Acting Therapy INVEGA® SUSTENNA® (paliperidone palmitate) Significantly Delayed Time to Relapse in Patients with Schizophrenia Compared to Daily Oral Antipsychotic
First prospective, randomized clinical trial to reflect context of “real world” issues in treating schizophrenia, including recent incarceration and substance abuse
SYLVANT™ (siltuximab) Receives FDA Approval to Treat Multicentric Castleman’s Disease (MCD)
First treatment approved for patients with rare blood disorder
Final Data from the Phase 2 COSMOS Study of Janssen’s Once-Daily Simeprevir in Combination with Sofosbuvir Presented at The International Liver Congress™ 2014 of the European Association for the Study of the Liver (EASL)
Additional Studies Presented in Genotype 1 and Genotype 4 Hepatitis C Patient Subgroups Underscore Benefit of Simeprevir-based Treatment Regimens
Supplemental New Drug Application for IMBRUVICA™ (ibrutinib) Submitted to the U.S. FDA
New submission based on positive Phase 3 data from the RESONATE™ trial
Janssen Initiates Phase 3 OPTIMIST Trials of Once-Daily Simeprevir in Combination with Once-Daily Sofosbuvir for the Treatment of Genotype 1 Chronic Hepatitis C
OPTIMIST represents the first Phase 3 studies of the two treatments in a regimen without interferon and ribavirin